HC Wainwright Cuts Earnings Estimates for Cogent Biosciences

Cogent Biosciences, Inc. (NASDAQ:COGT) – Stock analysts at HC Wainwright reduced their Q4 2026 EPS estimates for Cogent Biosciences in a research note issued on Monday, November 9th. HC Wainwright analyst R. Burns now forecasts that the technology company will earn ($0.67) per share for the quarter, down from their prior forecast of ($0.62). HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for Cogent Biosciences’ Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at $0.19 EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($1.09) EPS.

COGT has been the subject of several other research reports. Wall Street Zen cut shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a research note on Friday, October 2nd. Wedbush reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research report on Wednesday, September 16th. Guggenheim upped their price objective on Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Piper Sandler increased their price objective on Cogent Biosciences from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.57.

Cogent Biosciences Price Performance

Shares of COGT opened at $31.64 on Wednesday. Cogent Biosciences has a fifty-two week low of $27.74 and a fifty-two week high of $43.73. The firm’s 50 day moving average price is $31.74 and its 200 day moving average price is $35.44. The company has a market cap of $5.49 billion, a P/E ratio of -14.06 and a beta of 0.36. The company has a quick ratio of 13.57, a current ratio of 10.99 and a debt-to-equity ratio of 0.50.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings data on Thursday, November 5th. The technology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03).

Institutional Trading of Cogent Biosciences

A number of large investors have recently made changes to their positions in the company. Landscape Capital Management L.L.C. acquired a new stake in Cogent Biosciences in the third quarter valued at approximately $225,000. Voya Investment Management LLC grew its holdings in Cogent Biosciences by 6.4% during the 3rd quarter. Voya Investment Management LLC now owns 1,013,501 shares of the technology company’s stock worth $32,452,000 after acquiring an additional 60,744 shares in the last quarter. Virtus Advisers LLC increased its position in shares of Cogent Biosciences by 25.1% in the 3rd quarter. Virtus Advisers LLC now owns 14,419 shares of the technology company’s stock valued at $462,000 after purchasing an additional 2,895 shares during the last quarter. Aberdeen Group plc increased its position in shares of Cogent Biosciences by 49.7% in the 3rd quarter. Aberdeen Group plc now owns 588,628 shares of the technology company’s stock valued at $18,848,000 after purchasing an additional 195,394 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC raised its holdings in shares of Cogent Biosciences by 11.0% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 55,666 shares of the technology company’s stock valued at $1,782,000 after purchasing an additional 5,510 shares in the last quarter.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.